Deadline for Receipt of Abstracts: January 29, 2018
TARGET AUDIENCE The American Society for Experimental Neurotherapeutics (ASENT) was established for leaders in academia, government, advocacy and industry who are dedicated to advancing the development of improved therapies for diseases and disorders of the nervous system. The 20th ASENT Annual Meeting will offer participants the most current information in the field of neurotherapeutics.
FORMAT Abstracts are peer reviewed, and authors of accepted abstracts will be offered the opportunity to share their scientific data through podium platform presentations in the Pipeline Session or poster presentations.
CITATION All accepted abstracts will be published online in a Supplement to Neurotherapeutics, the Journal of the American Society for Experimental Neurotherapeutics, unless the submitting author requests otherwise.
All submitters will receive notification of the status of their abstracts and presentations for the meeting by February 5, 2018. All presenters are expected to cover their own travel and lodging, and pay the annual meeting registration fees.
Abstract Preparation: Abstracts must conform exactly to the instructions provided for electronic submission.
Abstracts must be submitted in English and all presentations will be in English.
Posters that have been previously presented at another scientific meeting may be presented at the ASENT Annual Meeting but the abstracts will not be published in Neurotherapeutics®.
Abstract Style: The abstract should describe original research broadly relevant to the goal of ASENT, which is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system. Please check your abstract carefully for typographical errors, misspellings, etc.
Title: The title should use capital letters where appropriate (not all capital letters). Do not use abbreviations in the title unless they are universally understood in the field (e.g. EEG, MRI, PET Scan).
Abstract Structure: The body of the abstract should be one paragraph with no subheadings but organized as follows:
A sentence stating the study's purpose.
A brief description of methods.
A summary of the results.
A statement of conclusions reached. Do not state simply the "the results will be discussed."
Author Names: List additional authors followed by affiliations, separated by semi-colons. Superscript numbers should be used after the author’s names in cases where there are multiple affiliations.
Abbreviations: Use standard abbreviations sparingly. Spell out abbreviations when first used.
Literature Citations: Literature citations are ordinarily not provided in abstracts. In cases where citations are required, these should be included in the body of the abstract and formatted according to the Neurotherapeutics® style.
Tables and Graphs: Simple tables and graphs may be included if they fit within the size constraints of the electronic program.
Drug Names: Use of both product and chemical names (capitalized) is acceptable.